MEDIBANK PRIVATE LTD(MPL.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

MPL.AU MEDIBANK PRIVATE LTD

Not Yet Opened 05-21 16:12:00 AEST

3.64

+0.02

+0.55%

High3.68	Low3.62	Vol7.08M
Open3.62	D1 Closing3.62	Amplitude1.52%
Mkt Cap10.02B	Tradable Cap10.01B	Total Shares2.75B
T/O25.84M	T/O Rate0.26%	Tradable Shares2.75B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"MPL.AU","market":"AU","secType":"STK","nameCN":"MEDIBANK PRIVATE LTD","latestPrice":3.64,"timestamp":1716271920000,"preClose":3.62,"halted":0,"volume":7082605,"delay":0,"nameEN":"MEDIBANK PRIVATE LTD","floatShares":2750363824,"shares":2754003240,"eps":0.249929,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"05-21 16:12:00 AEST","open":3.62,"high":3.675,"low":3.62,"amount":25842018,"amplitude":0.015193,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.249929,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716336000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":3.62,"dividendRate":0.042582,"openAndCloseTimeList":[[1716249600000,1716271200000]],"volumeRatio":0.7752498894737206,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/MPL.AU","defaultTab":"news","newsList":[{"id":"2437435200","title":"Medibank Focuses on Retention in Latest Give Back -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2437435200","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2437435200?lang=en_us&edition=fundamental","pubTime":"2024-05-21 06:52","pubTimestamp":1716245520,"startTime":"0","endTime":"0","summary":"2252 GMT - Medibank's decision to top up its policyholder give back looks to have disproportionately skewed to AHM customers over Medibank-brand customers, Goldman Sachs analysts Julian Braganza and Brian Kim say in a note. AHM customers got A$55 million and Medibank A$35 more in this top up. Eligible customers include those holding a policy at end-September for AHM customers and end-June for Medibank customers. This suggests to the analysts that there is a focus on customer retention coming from the top up, particularly for AHM, perhaps to offset a period of anticipated competitive pressure through to September. \"Medibank previously noted that claims savings were persisting through 2H FY 2024 versus revised lower expectations which foreshadowed scope for further give back,\" Goldman Sachs says. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2436153031","title":"BRIEF-Medibank Private Says Give Back Commitment Increased To A$305 Mln For Medibank & AHM Customers","url":"https://stock-news.laohu8.com/highlight/detail?id=2436153031","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2436153031?lang=en_us&edition=fundamental","pubTime":"2024-05-20 08:17","pubTimestamp":1716164220,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Medibank Private Ltd   :   * GIVE BACK COMMITMENT INCREASED TO A$305 MILLION FOR MEDIBANK AND AHM CUSTOMERSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2436112820","title":"Medibank lifts customer cashbacks to a healthy $305m as claims growth eases","url":"https://stock-news.laohu8.com/highlight/detail?id=2436112820","media":"Business News Australia","top":-1,"share":"https://ttm.financial/m/news/2436112820?lang=en_us&edition=fundamental","pubTime":"2024-05-20 00:00","pubTimestamp":1716134400,"startTime":"0","endTime":"0","summary":"Health insurer Medibank Private (ASX: MPL) has upped its cashback p...","market":null,"thumbnail":"https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/664a9a9f37c1f.jpg?v=2&m=4ba5cc9763bc4b325b5833bfdaac4875&lqip(10)","type":0,"news_type":0,"thumbnails":["https://assets.cdn.thewebconsole.com/S3WEB6082/a_images/664a9a9f37c1f.jpg?v=2&m=4ba5cc9763bc4b325b5833bfdaac4875&lqip(10)"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.businessnewsaustralia.com/articles/medibank-private-lifts-customer-cashbacks-to-a-healthy--305m-as-claims-growth-eases.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436941511","title":"Here are 3 reliable ASX shares I'd buy instead of the big four banks right now","url":"https://stock-news.laohu8.com/highlight/detail?id=2436941511","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2436941511?lang=en_us&edition=fundamental","pubTime":"2024-05-18 01:30","pubTimestamp":1715967000,"startTime":"0","endTime":"0","summary":"Thanks to the strong economy, the ASX bank share sector has done quite well during this period of higher interest rates. However, there are still danger signs, particularly with arrears rising. In the recent FY24 third-quarter update, we heard from Commonwealth Bank of Australia  how its arrears over 90 days have increased. At March 2023, home loans at least 90 days overdue were 0.44% of its loan book, but that had increased to 0.61% at March 2024. What could this mean for bank earnings?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/18/here-are-3-reliable-asx-shares-id-buy-instead-of-the-big-four-banks-right-now/","is_publish_highlight":false,"gpt_icon":0},{"id":"2436695302","title":"PharmAust set to transform MND therapy landscape as monepantel receives FDA orphan drug designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2436695302","media":"Small Caps","top":-1,"share":"https://ttm.financial/m/news/2436695302?lang=en_us&edition=fundamental","pubTime":"2024-05-17 10:09","pubTimestamp":1715911751,"startTime":"0","endTime":"0","summary":"PharmAust  has achieved a major breakthrough in plans to commercialise its monepantel  treatment for motor neurone disease with the receipt of an orphan drug designation  from the US Food and Drug Administration .The ODD status assists companies in the development of safe and effective treatments for rare diseases and disorders.It also provides incentives including tax credits, grants, waiver of some administrative fees for clinical trials and seven years of market exclusivity following drug approval.Motor neurone disease  is the name given to a group of diseases in which the nerve cells that control muscles undergo degeneration and die.Amyotrophic lateral sclerosis  is a subtype of MND.MND is the widely used generic term in the United Kingdom, Australia and parts of Europe, whereas ALS is more commonly used in the United States, Canada and South America.It is also known in the US as “Lou Gehrig’s disease” after a famous New York Yankees baseball player who lost his life to the conditi","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/05/PharmAust-ASX-PAA-FDA-orphan-drug-designation-monepantel-MPL.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/05/PharmAust-ASX-PAA-FDA-orphan-drug-designation-monepantel-MPL.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/pharmaust-mnd-therapy-monepantel-fda-orphan-drug-designation/","is_publish_highlight":false,"gpt_icon":0},{"id":"2435726355","title":"With $1,000 to invest, should I buy ASX growth stocks or income shares?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435726355","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2435726355?lang=en_us&edition=fundamental","pubTime":"2024-05-15 10:19","pubTimestamp":1715739546,"startTime":"0","endTime":"0","summary":"There's an age-old question about whether it's best to invest in ASX growth stocks or ASX income shares. I'm going to consider the question from the perspective of investing $1,000. Saving up $1,000 to invest is an achievement amid this high cost of living. What's going to be the best place to invest it?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/15/with-1000-to-invest-should-i-buy-asx-growth-stocks-or-income-shares/","is_publish_highlight":false,"gpt_icon":0},{"id":"2435055636","title":"Has Medibank Private Limited's (ASX:MPL) Impressive Stock Performance Got Anything to Do With Its Fundamentals?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435055636","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2435055636?lang=en_us&edition=fundamental","pubTime":"2024-05-14 07:05","pubTimestamp":1715641501,"startTime":"0","endTime":"0","summary":"Medibank Private (ASX:MPL) has had a great run on the share market with its stock up by a significant 6.0% over the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/7212000-choice2-main-header/1585186560665","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/7212000-choice2-main-header/1585186560665"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/insurance/asx-mpl/medibank-private-shares/news/has-medibank-private-limiteds-asxmpl-impressive-stock-perfor","is_publish_highlight":false,"gpt_icon":0},{"id":"2434724228","title":"Why I'd buy high-yield ASX dividend shares for superannuation in retirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2434724228","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2434724228?lang=en_us&edition=fundamental","pubTime":"2024-05-12 02:30","pubTimestamp":1715452200,"startTime":"0","endTime":"0","summary":"I think high-yield ASX dividend shares can be a very effective pick for superannuation in retirement because of cash flow requirements and potential taxation advantages.  Superannuation is usually one of the most valuable assets for a lot of Aussies. In retirement, it may be the main  source of income, depending on whether someone gets the age pension or if they have other non-superannuation assets to generate income. What makes dividend income appealing in retirement?What assets are good choices for superannuation in retirement?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/12/why-id-buy-high-yield-asx-dividend-shares-for-superannuation-in-retirement/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434867199","title":"Top ASX shares to buy for your superannuation fund in May 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434867199","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2434867199?lang=en_us&edition=fundamental","pubTime":"2024-05-11 02:00","pubTimestamp":1715364000,"startTime":"0","endTime":"0","summary":"Deciding which ASX shares to buy for your superannuation fund is not easy. After all, you have toiled all your working life to earn this money, and hopefully, it will afford you a happy, financially secure, and stress-free retirement.Likewise, your super investment is not something you should constantly meddle with. This means you'll want the ASX shares within it to be high-quality companies you can hold for the long term — not risky stocks you need to dip in and out of regularly.Whether you run your own self-managed super fund  or simply like to add a few personal touches to your retail super fund, read on!Because we asked our Foolish contributors which ASX shares they reckon deserve a place in your superannuation fund in May.6 best ASX shares for your super fund right now . What it does: This ASX exchange-traded fund  gives investors exposure to a diversified portfolio of attractively priced US companies with sustainable competitive advantages.Over the past decade, the index this ETF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/11/top-asx-shares-to-buy-for-your-superannuation-fund-in-may-2024/","is_publish_highlight":false,"gpt_icon":0},{"id":"2434053569","title":"PharmAust to build on laboratory success with management changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2434053569","media":"Small Caps","top":-1,"share":"https://ttm.financial/m/news/2434053569?lang=en_us&edition=fundamental","pubTime":"2024-05-09 10:00","pubTimestamp":1715220018,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company PharmAust  is looking to build on the successful development of its monepantel  treatment with a rejuvenation of its board of directors.Dr Roger Aston, Robert Bishop and Dr Thomas Duthy have resigned from the board, while Sam Wright has been appointed interim chair.Mr Wright has been a director of the company since October 2008 and remains a top 10 shareholder in PharmAust.Marcus Hughes, another major shareholder, has been named as a non-executive director.John Clark has been promoted to the position of managing director after being named interim chief executive officer in late April.“We’ve made new additions to the board of directors with the drive, requisite experience and skillset that will allow for the continued development and success of PharmAust and MPL at this pivotal stage of the company,” Mr Wright said.Since joining PharmAust, Mr Clark has established relationships with multiple key stakeholders involved in the clinical development of MP","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/05/PharmAust-ASX-PAA-board-management-changes.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/05/PharmAust-ASX-PAA-board-management-changes.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/pharmaust-build-laboratory-success-management-changes/","is_publish_highlight":false,"gpt_icon":0},{"id":"2433381767","title":"BUZZ-Australia's Medibank falls; Brokerage Jarden raises PT, EPS forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2433381767","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433381767?lang=en_us&edition=fundamental","pubTime":"2024-05-08 11:05","pubTimestamp":1715137503,"startTime":"0","endTime":"0","summary":"** Shares of health insurance provider Medibank    down 0.8%, even as brokerage firm Jarden says it expects co's health insurance net margins to lift to a high of 9.3% in 2H24E due to lower claims inf","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433265733","title":"BRIEF-Medibank Private Says On Track To Deliver FY24 Resident Policyholder Growth Of 1.2% - 1.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433265733","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2433265733?lang=en_us&edition=fundamental","pubTime":"2024-05-07 09:08","pubTimestamp":1715044112,"startTime":"0","endTime":"0","summary":"May 7  - Medibank Private Ltd   :   * MEDIBANK SHARES BUSINESS UPDATE AND HEALTHCARE INSIGHTS   * REMAIN ON TRACK IN AIM TO DELIVER RESIDENT POLICYHOLDER GROWTH OUTLOOK OF 1.2% - 1.5% FOR FY24   * EXPECTED CLAIMS GROWTH PER POLICY UNIT FOR FY24 AMONGST RESIDENT POLICYHOLDERS ANTICIPATED TO BE AT LOWER END OF 2.2% - 2.4% RANGE   * COMPETITIVE INTENSITY IN RESIDENT INDUSTRY REMAINED LARGELY UNCHANGED IN THIRD QUARTER AND IS EXPECTED TO PERSIST THROUGH 4QFurther company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433265301","title":"Down 10% since mid-March, are Medibank shares a buy or a sell?","url":"https://stock-news.laohu8.com/highlight/detail?id=2433265301","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2433265301?lang=en_us&edition=fundamental","pubTime":"2024-05-07 09:01","pubTimestamp":1715043714,"startTime":"0","endTime":"0","summary":"The Medibank Private Ltd  share price has dropped around 10% in the last couple of months, as we can see on the chart below. In this article, I'm going to look at whether the ASX healthcare share is a buy or if it's one to avoid after announcing a business update.  Medibank is the largest private health insurer in Australia, with its Medibank and ahm brands. Let's first consider why some investors may be negative on the company. Why be negative on Medibank shares?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/05/07/down-10-since-mid-march-are-medibank-shares-a-buy-or-a-sell/","is_publish_highlight":false,"gpt_icon":0},{"id":"2431333121","title":"PharmAust gears for major clinical milestones in 2024, following strong start and FDA feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2431333121","media":"Small Caps","top":-1,"share":"https://ttm.financial/m/news/2431333121?lang=en_us&edition=fundamental","pubTime":"2024-04-30 10:43","pubTimestamp":1714444994,"startTime":"0","endTime":"0","summary":"PharmAust  is preparing to undertake a number of key activities in its treatment development schedule after completing a strong start to the year.The clinical-stage biotechnology company highlighted a number of milestones in releasing its quarterly activities report for the period ended 31 March 2024.“The March quarter was particularly important and successful for PharmAust, headlined by the positive Phase 1 trial top-line data for monepantel  in motor neurone disease /amyotrophic lateral sclerosis ,” interim chief executive officer John Clark said.“This gives us a strong foundation to push forward with both the open-label extension study and the pivotal adaptive Phase 2/3 clinical trial.”“The positive Food and Drug Administration  feedback has provided us with a clear path towards potential accelerated approval,” he added.PharmAust also expanded its highly-experienced leadership group with key appointments to both the management team and the board.Under these agreements, Syngene will ","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/04/PharmAust-ASX-PAA-quarterly-report-MND-ALS-MPL.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/04/PharmAust-ASX-PAA-quarterly-report-MND-ALS-MPL.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/pharmaust-major-clinical-milestones-2024-strong-start-fda-feedback/","is_publish_highlight":false,"gpt_icon":0},{"id":"2430632702","title":"Cost of Living Uptick May Pressure Aussie Health Insurers -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2430632702","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2430632702?lang=en_us&edition=fundamental","pubTime":"2024-04-26 06:41","pubTimestamp":1714084860,"startTime":"0","endTime":"0","summary":"2241 GMT - Higher cost of living will likely see more Australians reconsider private health insurance, Jefferies analysts say in a note. It says that this, alongside a lower migration rate, may lead to a decline in PHI participation. Still, it reckons this could be tempered by FY 2023 elective surgery waiting times which are at 20-year highs as public hospitals work to clear the pandemic-related backlog. \"We expect participation rates to moderate slowly as consumers self-select whilst the public system works to return to business as usual,\" Jefferies says. It keeps a buy call on Medibank and moves Nib to a hold from buy, saying it likes the former's market leading share. This, Jefferies says, allows it sharper negotiations with hospitals, and lower weighting to international and travel policies. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2429169763","title":"PharmAust appoints interim CEO as company plans for pivotal Phase 2/3 study","url":"https://stock-news.laohu8.com/highlight/detail?id=2429169763","media":"Small Caps","top":-1,"share":"https://ttm.financial/m/news/2429169763?lang=en_us&edition=fundamental","pubTime":"2024-04-23 17:51","pubTimestamp":1713865874,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company PharmAust  has announced that chief executive officer Dr Michael Thurn has resigned from the role and will leave the company in four months.Chief operating officer John Clark has been appointed to the role of interim chief executive officer and will be assisted by Dr Thurn and the PharmAust board of directors during the transition period.Mr Clark has worked in the pharmaceutical industry for more than 20 years and been involved with clinical trials across numerous therapeutic areas and multiple geographical regions.Before joining PharmAust, he served as senior project manager at a global contract research organisation, leading the clinical operations team and providing cross-functional oversight on national clinical trials.Since joining PharmAust, Mr Clark has established relationships with key stakeholders involved with the clinical development of lead drug candidate monepantel  and has attended worldwide pharmaceutical conferences as a PharmAust d","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/04/PharmAust-ASX-PAA-interim-CEO-company-plans-pivotal-Phase-2-3-study.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/04/PharmAust-ASX-PAA-interim-CEO-company-plans-pivotal-Phase-2-3-study.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://smallcaps.com.au/pharmaust-appoints-interim-ceo-company-plans-phase-2-3-study/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429180070","title":"PharmAust CEO sayanora triggers stock plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2429180070","media":"The Market Herald","top":-1,"share":"https://ttm.financial/m/news/2429180070?lang=en_us&edition=fundamental","pubTime":"2024-04-23 10:08","pubTimestamp":1713838080,"startTime":"0","endTime":"0","summary":"Clinical-stage biotechnology company, PharmAust , shares have fallen as much as 24 per cent so far this morning, following the resignation of its CEO, Dr. Michael Thurn, citing personal reasons.PharmAust’s Chief Operating Officer, John Clark, has stepped in as interim CEO.During Dr. Thurn’s tenure, he led pivotal initiatives such as the Phase 1 MEND Study of monepantel  for treating motor neurone disease . He also played a key role in preparing for a Phase 2/3 clinical study in human patients with MND/ALS.Under his guidance, the company executed two capital raisings.“We are delighted to appoint John to the role of interim CEO to work with the Board and PharmAust team at this exciting time, as we aggressively pursue the Company’s clinical and commercial objectives, including development and intended commercialisation of monepantel for MND/ALS treatment.” Pharmaust chairman Dr. Roger Aston said.Since joining PharmAust, he’s fostered relationships with key stakeholders involved in the cli","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/pharmaust-ceo-sayanora-triggers-stock-plunge-2024-04-23/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429090386","title":"3 ASX stocks to benefit from Australia's ageing population","url":"https://stock-news.laohu8.com/highlight/detail?id=2429090386","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2429090386?lang=en_us&edition=fundamental","pubTime":"2024-04-23 03:30","pubTimestamp":1713814200,"startTime":"0","endTime":"0","summary":"ASX stocks that benefit from long-term tailwinds can provide a real boost for earnings over the long term. I think the ageing population tailwind is strong and one of the clearest tailwinds that's going to happen.The 2023 intergenerational report said over the next 40 years the number of Australians aged 65 and over will more than double and the number aged 85 and over will more than triple. The number of people aged at least 100 is expected to increase six-fold.Which businesses could benefit from the growing number of older Australians?I think the three ASX stocks below could be leading beneficiaries of the tailwind.As the number of older Aussies increases, it should mean a growing amount of people moving from the accumulation phase to the retirement phase with their money, which could lead to stronger demand for annuities.Australian superannuation assets are expected to increase to more than $9 trillion in the next 20 years, with 2.5 million Australians entering retirement over the n","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/23/3-asx-stocks-to-benefit-from-australias-ageing-population/","is_publish_highlight":false,"gpt_icon":0},{"id":"2429992332","title":"Here's the Rio Tinto dividend forecast through to 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2429992332","media":"MotleyFool","top":-1,"share":"https://ttm.financial/m/news/2429992332?lang=en_us&edition=fundamental","pubTime":"2024-04-22 13:43","pubTimestamp":1713764602,"startTime":"0","endTime":"0","summary":"Rio Tinto Ltd  shares are a popular option for Australian income investors. And it really is not hard to see why. Over the last decade, the mining giant has rewarded its shareholders with billions of dollars of fully franked dividends. For example, in FY 2023, Rio Tinto reported underlying earnings of US$11.8 billion, which allowed its board to declare total dividends of US$4.35 per share. This equates to a total pay out of US$7.1 billion . To put that into context, that is more than the market capitalisations of Qantas Airways Limited  and Medibank Private Ltd . It is also just a touch short of the A$12 billion valuation of lithium giant Pilbara Minerals Ltd . But those dividends have been and gone. What's next for the Rio Tinto dividend?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/04/22/heres-the-rio-tinto-dividend-forecast-through-to-2028/","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.medibank.com.au","stockEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0139},{"period":"3month","weight":-0.0381},{"period":"6month","weight":0.0548},{"period":"1year","weight":0.0798},{"period":"ytd","weight":0.043}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.0623},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.1364},{"period":"1year","weight":0.1403},{"period":"ytd","weight":0.1221}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Medibank Private Limited, an integrated healthcare company, provides private health insurance and health solutions in Australia. It operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment offers private health insurance products, including hospital cover that provides members with health cover for hospital treatments; and ancillary cover, which offers members with health cover for healthcare services, such as dental, optical, and physiotherapy. This segment also provides health insurance products to overseas visitors and overseas students. The Medibank Health segment offers health management and telehealth services to government and corporate customers, as well as distributes travel, life, and pet insurance products. The company underwrites its health insurance products under the Medibank and ahm brands. Medibank Private Limited was founded in 1976 and is based in Docklands, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.01358},{"month":2,"riseRate":0.4,"avgChangeRate":-0.001238},{"month":3,"riseRate":0.8,"avgChangeRate":0.026273},{"month":4,"riseRate":0.7,"avgChangeRate":0.019325},{"month":5,"riseRate":0.555556,"avgChangeRate":-0.001733},{"month":6,"riseRate":0.666667,"avgChangeRate":0.020903},{"month":7,"riseRate":0.666667,"avgChangeRate":0.029594},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.033205},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.020623},{"month":10,"riseRate":0.666667,"avgChangeRate":0.005144},{"month":11,"riseRate":0.7,"avgChangeRate":0.022202},{"month":12,"riseRate":0.4,"avgChangeRate":0.009835}],"exchange":"ASX","name":"MEDIBANK PRIVATE LTD","nameEN":"MEDIBANK PRIVATE LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MEDIBANK PRIVATE LTD(MPL.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MEDIBANK PRIVATE LTD(MPL.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MEDIBANK PRIVATE LTD,MPL.AU,MEDIBANK PRIVATE LTD股票,MEDIBANK PRIVATE LTD股票老虎,MEDIBANK PRIVATE LTD股票老虎国际,MEDIBANK PRIVATE LTD行情,MEDIBANK PRIVATE LTD股票行情,MEDIBANK PRIVATE LTD股价,MEDIBANK PRIVATE LTD股市,MEDIBANK PRIVATE LTD股票价格,MEDIBANK PRIVATE LTD股票交易,MEDIBANK PRIVATE LTD股票购买,MEDIBANK PRIVATE LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MEDIBANK PRIVATE LTD(MPL.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MEDIBANK PRIVATE LTD(MPL.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction